awmsg logo



epoetin delta (Dynepo®)


Reference No. 129

Publication date:
20/03/2008


Appraisal information

epoetin delta (Dynepo®) solution for injection


Company: Shire Pharmaceuticals Ltd
BNF category: Nutrition and blood
NMG meeting date: 16/01/2008
AWMSG meeting date: 14/02/2008
   
   
Submission Type: Full Submission
Status: Marketing authorisation withdrawn
Advice No: 0408
Ministerial ratification: 06/03/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. Epoetin delta (Dynepo®) is recommended for use in patients on dialysis (and in patients not on dialysis) within NHS Wales for the treatment of anaemia in patients with chronic renal failure. Epoetin delta (Dynepo®) should only be initiated by specialists experienced in the treatment of chronic renal failure. AWMSG are of the opinion that epoetin delta (Dynepo®) may be suitable for shared care agreements within NHS Wales. Existing shared care protocols for current erythropoietin stimulating agents (ESAs) may need to be reviewed in light of this decision.
Final Appraisal Recommendation (FAR)
Download